This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by O’Shaughnessy, J. Search for Related Content PubMed PubMed Citation Articles by O’Shaughnessy, J.

Extending Survival with Chemotherapy in Metastatic Breast Cancer

Baylor-Sammons Cancer Center, Dallas, Texas, USA

Key Words. Metastatic • Overall survival • Docetaxel • Paclitaxel • Trastuzumab • Bevacizumab

Correspondence: Joyce O’Shaughnessy, M.D., Baylor-Sammons Cancer Center, 3535 Worth St., Collins 5, Dallas, Texas 75246, USA. Telephone: 214-370-1795; Fax: 214-370-1850; e-mail: joyce.o'shaughnessy{at}usoncology.com

Metastatic breast cancer (MBC) remains essentially incurable, and goals of therapy include the palliation of symptoms, delay of disease progression, and prolongation of overall survival time without negatively impacting quality of life. Anthracycline and taxane-based therapies have traditionally shown the highest degree of activity in MBC. Though numerous randomized clinical trials have shown improvements in overall response rates, few have found clear survival benefits. In recent years, however, there has been a small but growing series of clinical trials demonstrating modest, but meaningful survival advantages in metastatic disease. A common feature in many of these trials has been the use of a taxane, and more recently, a taxane combined with an antimetabolite. In addition, the development of targeted biologic agents active against MBC, such as trastuzumab and bevacizumab, has demonstrated great potential for enhancing the effects of chemotherapy and producing meaningful survival improvements. The role of the taxanes, antimetabolites, and biologics in extending survival in MBC is discussed.

This article has been cited by other articles:

				J. Schwartz and S. T. Wong Introduction Am. J. Health Syst. Pharm., December 1, 2009; 66(23_Supplement_6): S1 - S2. [Full Text] [PDF]

				B. Paul, J. A. Trovato, and J. Thompson Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer Am. J. Health Syst. Pharm., September 15, 2008; 65(18): 1703 - 1710. [Abstract] [Full Text] [PDF]

				X. Pivot, P. Koralewski, J. L. Hidalgo, A. Chan, A. Goncalves, G. Schwartsmann, S. Assadourian, and J. P. Lotz A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients Ann. Onc., September 1, 2008; 19(9): 1547 - 1552. [Abstract] [Full Text] [PDF]

				J. A. Waddell Introduction Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S2 - S3. [Full Text] [PDF]

				L. B. Michaud Treatment-experienced breast cancer Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S4 - S9. [Abstract] [Full Text] [PDF]

				S. Goodin Novel cytotoxic agents: Epothilones Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S10 - S15. [Abstract] [Full Text] [PDF]

				T. Vu, S. Ellard, C. H. Speers, S. C. M. Taylor, M. L. de Lemos, F. Hu, K. Kuik, and I. A. Olivotto Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation Ann. Onc., March 1, 2008; 19(3): 461 - 464. [Abstract] [Full Text] [PDF]

				H. Roche, L. Yelle, F. Cognetti, L. Mauriac, C. Bunnell, J. Sparano, P. Kerbrat, J.-P. Delord, L. Vahdat, R. Peck, et al. Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy J. Clin. Oncol., August 10, 2007; 25(23): 3415 - 3420. [Abstract] [Full Text] [PDF]

				A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, H. -J. Senn, and Panel Members Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann. Onc., July 1, 2007; 18(7): 1133 - 1144. [Abstract] [Full Text] [PDF]

				D. Tripathy Capecitabine in Combination with Novel Targeted Agents in the Management of Metastatic Breast Cancer: Underlying Rationale and Results of Clinical Trials Oncologist, April 1, 2007; 12(4): 375 - 389. [Abstract] [Full Text] [PDF]